An Open-label Positron Emission Tomography (PET) Study to Investigate the Heterogeneity of 68Ga-FAPI Uptake Predicting the Response of T-DXd Treatment for Brain Metastasis in Patients with HER2-positive Advanced or Metastatic Breast Cancer
Latest Information Update: 04 Feb 2025
Price :
$35 *
At a glance
- Drugs Trastuzumab-deruxtecan (Primary)
- Indications Brain metastases; HER2 positive breast cancer
- Focus Therapeutic Use
- 04 Feb 2025 New trial record